Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer

Prior treatment

• Combined with the following diseases or medical history:
  • Other malignant tumors have occurred or are present at the same time within\<3 years before the first administration.
  • Inability to tolerate multiple factors affecting oral medication due to any reason;
  • Common Terminology Criteria for Adverse Events (CTCAE) 5.0 \> grade 1 therapeutic toxicity caused by any previous treatment that has not been completely relieved, excluding hair loss;
  • Major surgical treatment or obvious traumatic injury was received within 4 weeks before the first administration;
  • The presence of unhealed wounds, fractures, gastric and duodenal active ulcers, persistent positive fecal occult-blood, ulcerative colitis, or other conditions determined by investigators that may cause gastrointestinal bleeding or perforation;
  • Arteriovenous thrombosis, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc., occurred within 6 months before the first medication;
  • Those who have a history of psychotropic drug abuse and cannot abstain or have mental disorders;
  • Subjects with any severe and/or uncontrollable disease；
• Tumor related symptoms and treatment:
  • Had received chemotherapy, radiation, or other anticancer therapy within 4 weeks prior to first dose;
  • Within 2 weeks before the first dose, received Chinese Traditional drugs with anti-tumor indications specified in theNational Medical Products Administration (NMPA) approved drug instructions
  • Previously treated with anti-angiogenic drugs such as Cabozantinib, Anlotinib, Endostar and Bevacizumab;
  • Imaging Computed Tomography (CT)or Magnetic Resonance Imaging (MRI) shows that the tumor has invaded important blood vessels or the investigator determines that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during the follow-up study;
  • There is a history of interstitial lung disease, severe impairment of lung function, severe pulmonary fibrosis, severe radiation pneumonia, drug-induced lung disease, and evidence of severe active lung inflammation indicated by chest CT examination during screening;
  • There are uncontrolled pleural effusion, ascites and moderate or above pericardial effusion requiring repeated drainage;
  • Patients with brain metastases accompanied by symptoms or symptoms controlled for less than 2 weeks;
• Patients who have participated in and used other antitumor investigational drugs within 4 weeks before the first dose;
• Patients with concomitant diseases that, in the opinion of the investigators, seriously endanger the safety of the patients or affect the completion of the study, or who are not suitable for inclusion for other reasons.

Other illness

• Central squamous cell carcinoma (lung cancer subjects) with great risk of hemoptysis;

• Subjects with advanced lung cancer or ovarian cancer confirmed by histopathology or cytology;
• Age: 18\~75 years old (when signing the informed consent form); Eastern Cooperative Oncology Group (ECOG) score: 0-1;
• At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1;
• Normal function of main organs
• The serum Human Chorionic Gonadotropin (HCG) test of female patients of childbearing age must be negative within 7 days before study enrollment and must be non-lactating; The patient should agree to use contraception during the study period and within 6 months after the end of the study period;Male subjects should agree to use contraception during the study period and for 6 months after the study period ends;
• The patient voluntarily joined the study and signed the informed consent form, with good compliance.